Silver Book Fact

According to the Pharmaceutical Research and Manufacturers of America, one of the most promising medicines in development uses normal human cells to enhance brain levels of dopamine, the neurotransmitter deficient in Parkinson’s disease.

2006 Report: Medicines in development for neurological disorders. http://www.phrma.org/files/Neurologic_2006.pdf. Published 2006

Reference

Title
2006 Report: Medicines in development for neurological disorders
Publisher
PhRMA
Publication Date
Published 2006
Authors
PhRMA
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.  
  • The present value QUALY gains associated with a new drug that by 2010 could delay disease onset by 1, 3, and 5 years. The dollar value estimates range from approximately…  
  • Medicaid Costs, Slowed Progression  
  • An Alzheimer’s disease treatment breakthrough that slowed progression and began to show its effects in 2015, would reduce Medicaid costs for people with the disease by $14 billion in 2020–from…  
  • Delaying the onset of Alzheimer’s by only 5 years could reduce the number of people with Alzheimer’s by almost 50% after 50 years.